help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow eLetters: Submit a response to this article
Services
Right arrow E-mail this article link to a friend
Right arrow Alert me to new issues of the journal
Right arrow Reprints/Permissions
Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage
Oncologist Stein et al. 13: 1055

Supplemental Data

Files in this Data Supplement:



This Article
Right arrow Abstract
Right arrow Full Text
Right arrow eLetters: Submit a response to this article
Services
Right arrow E-mail this article link to a friend
Right arrow Alert me to new issues of the journal
Right arrow Reprints/Permissions

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS